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Abstract
WW domain binding protein 1-like (WBP1L), also known as outcome predictor of 
acute leukaemia 1 (OPAL1), is a transmembrane adaptor protein, expression of which 
correlates with ETV6-RUNX1 (t(12;21)(p13;q22)) translocation and favourable prog-
nosis in childhood leukaemia. It has a broad expression pattern in haematopoietic 
and in non-haematopoietic cells. However, its physiological function has been un-
known. Here, we show that WBP1L negatively regulates signalling through a critical 
chemokine receptor CXCR4 in multiple leucocyte subsets and cell lines. We also show 
that WBP1L interacts with NEDD4-family ubiquitin ligases and regulates CXCR4 
ubiquitination and expression. Moreover, analysis of Wbp1l-deficient mice revealed 
alterations in B cell development and enhanced efficiency of bone marrow cell trans-
plantation. Collectively, our data show that WBP1L is a novel regulator of CXCR4 
signalling and haematopoiesis.
     |  1981BORNA et Al.
1  | INTRODUC TION
WW domain binding protein 1-like (WBP1L) also known as outcome 
predictor of acute leukaemia 1 (OPAL1) has attracted attention 
because of a report showing that its elevated expression at mRNA 
level correlates with favourable outcome in childhood acute lym-
phoblastic leukaemia (ALL).1 These data suggested that it could po-
tentially serve as a prognostic marker. Later, it was shown that its 
levels are particularly increased in B cell progenitor ALL (BCP-ALL) 
with chromosomal translocation t(12;21)(p13;q22), which results in 
expression of ETV6-RUNX1 fusion transcription factor.2,3 In BCP-
ALL, this translocation is associated with good prognosis, which 
likely explains the correlation between WBP1L expression and fa-
vourable outcome.2 However, it is not known whether WBP1L func-
tionally contributes to it.
ETV6, a fusion partner in ETV6-RUNX1, is a transcriptional re-
pressor and WBP1L is one of its target genes.4-6 In general, ETV6 
targets are of high interest because of critical importance of ETV6 in 
haematopoiesis and its involvement in leukaemia. Around 30 fusions 
of ETV6 to different partner genes and a number of mutations in 
ETV6 have been identified so far, many of them implicated in various 
haematological malignancies of myeloid and lymphoid origin.7,8 In 
addition, its critical role in normal haematopoiesis has been revealed 
in studies of ETV6-deficient mice, which show profound defects 
in haematopoietic stem and progenitor cell function and inability 
of these cells to reconstitute haematopoiesis after bone marrow 
transplantation.9,10
Bioinformatic sequence analysis revealed that WBP1L is a trans-
membrane adaptor protein with a very short extracellular/luminal 
part followed by a single transmembrane domain and a larger cy-
toplasmic tail.11 Although relatively short, the extracellular/lumi-
nal part presumably forms a small compact domain held together 
by disulphide bridges formed among cysteines in the C*C*CC*CC 
motif.11 The cytoplasmic part of WBP1L contains several potential 
interaction motifs corresponding to the consensus sequence of WW 
domain binding motifs L-P-X-Y or P-P-X-Y.11
Except for the limited bioinformatics analysis, WBP1L protein 
remained completely uncharacterized. Its physiological function 
has been unknown and whether it has any functional features that 
may link it to normal haematopoiesis or neoplasia has never been 
investigated. Here, we show that it binds several members of the 
NEDD4-family of ubiquitin ligases and that its deficiency results in 
enhanced surface expression and signalling of critical chemokine 
receptor CXCR4. WBP1L deficiency also results in alterations in 
B cell development and altered dynamics of stem and progenitor 
cells in the bone marrow. Taken together, we establish the role of 
WBP1L in CXCR4 signalling and in normal haematopoiesis. These 
findings also form the basis for further research on its potential 
role in leukaemia.
2  | MATERIAL S AND METHODS
2.1 | Protein isolation, detection and quantification 
assays
Immunoprecipitations (IP) and immunoblotting were performed 
essentially as reported with adjustments described in online sup-
plement. Western blot quantifications were carried out using 
Azure c300 imaging system (Azure Biosystems) and Aida Image 
Analysis software (Elysia-raytest). WBP1L expression in B cell 
lines was analysed by size exclusion chromatography-microsphere-
based affinity proteomics analysis described in detail here,3 and 
the data were quantified using Matlab (MathWorks). Tandem 
purification of WBP1L was based on the following publication12 
with modifications described in online supplement. WBP1L pal-
mitoylation was analysed using metabolic labelling with palmitic 
acid analogue 17ODYA followed by reaction with biotin-azide and 
enrichment on streptavidin-coupled beads as described in detail in 
online supplement.
2.2 | Antibodies
Antibodies are listed in Tables S1 and S2. WBP1L antisera were 
generated by immunization of rabbits with KLH-conjugated peptide 
from WBP1L C-terminus while WBP1L monoclonal antibodies were 
prepared by standard hybridoma technology after immunization of 
mice with recombinant C-terminal part of murine WBP1L protein as 
described in online supplement.
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2.3 | Cloning, qPCR, DNA transfection, virus 
preparation and cell infection
cDNA was generated using Quick-RNA kit (Zymo Research), revert aid 
reverse transcriptase (Thermo-Fisher) and oligo-dT primer. qPCR re-
actions were run on LightCycler 480 Instrument II using LightCycler 
480 SYBR Green I Master mix (Roche). List of qPCR primers is in Table 
S3. For construct preparation see online supplement and Table S4. 
Phoenix cell transfection, virus generation and cell transduction were 
performed as described.13 For lentivirus production, the procedure was 
to a minor extent modified as described in online supplement. Infected 
cells were sorted on Influx (BD) or selected on G418 (Thermo-Fisher).
2.4 | Mouse experiments, homing assays
Wbp1l−/− mice (Wbp1ltm2a(EUCOMM)Hmgu) on C57Bl/6J genetic back-
ground were obtained from International Mouse Phenotyping 
Consortium. In these mice, gene trap flanked by FRT sites followed 
by coding region of exon 5 surrounded by LoxP sites were inserted 
into Wbp1l locus by homologous recombination (Wbp1l−/−). Mice 
were bred in specific pathogen free conditions. To obtain induc-
ible Wbp1lfl/flCreERT mice, we crossed animals of the Wbp1l−/− strain 
to B6.Cg-Tg (ACTFLPe)9205 Dym/J mice to remove the gene trap, 
and subsequently, to B6.129-Gt(ROSA)26Sortm1(cre/ERT2)Tyj/J animals. 
Both mouse strains were purchased from the Jackson Laboratory 
(Bar Harbor). To achieve Wbp1l deletion, mice were injected intra-
peritoneally with five daily doses of 2 mg of tamoxifen (Merck) in 
corn oil (Merck). For homing and transplantation assays, congenic 
Ly5.1 (C57BL/6NCr) or Ly5.1/Ly5.2 (C57Bl/6J) heterozygote recipi-
ents were sublethally (three Grey) or lethally (seven Grey) irradi-
ated, followed by injection of transplanted cells into the tail vain. 
For experiments we used 8- to 12–week-old sex and age matched 
animals. Housing of mice and in vivo experiments were performed 
in compliance with local legal requirements and ethical guidelines. 
The Animal Care and Use Committee of the Institute of Molecular 
Genetics approved animal care and experimental procedures (Ref. 
No. 69/2014, 6/2016).
2.5 | Transwell migration
1 × 105 Cells in DMEM with 0.2% BSA were plated in the upper well 
of 5µm pore Transwell apparatus (Corning). After 4 hours, migrated 
cells in the bottom well were counted using a flow cytometer (LSRII; 
BD).
F I G U R E  1   WBP1L is a palmitoylated glycoprotein, broadly expressed in haematopoietic cells. (A) Verification of new WBP1L rabbit 
antisera specificity on the lysates of HEK293 cells transfected or not with WBP1L construct. (B) Western blot analysis of WBP1L expression 
in murine leucocyte subsets. T cells (CD3+), B cells (CD43−, CD11b−) and neutrophils (Ly6G+) were isolated from the spleen or bone marrow. 
Bone marrow-derived macrophages (BMDM) and bone marrow-derived dendritic cells (BMDC) were differentiated in vitro from murine 
bone marrow. N = 3. (C) Expression of WBP1L in BCP-ALL cell lines was probed using size exclusion chromatography-microsphere-based 
affinity Proteomics method. Expression in ETV6-RUNX1+ B cell line REH and ETV6-RUNX1− lines TOM-1, NALM-6, NALM-24, RS4.11 
and SUB B15 was probed by two antibody clones to WBP1L (OPAL-01, OPAL-02) and quantified as an area under the curve on parts of 
chromatograms representing fractions corresponding to WBP1L (N = 1 per antibody clone). (D) Expression of WBP1L mRNA in different 
ETV6-RUNX1−/− REH clones from two independent sources of REH cells. Data are plotted as 2-Δct (N = 3). (E) Schematic representation of 
WBP1L structure and conserved sequence motifs (F) Analysis of WBP1L glycosylation in BMDM. BMDM treated or not with 1 or 10 µmol/L 
tunicamycin (overnight) were subjected to WBP1L immunoprecipitation followed by immunoblotting with WBP1L antisera. β-actin was 
stained in the corresponding cell lysates (N = 2). Irrelevant lines from the blot image were removed and replaced with a vertical dividing line. 
(G) Analysis of palmitoylation of WBP1L. HEK293 cells expressing WBP1L-FLAG-STREP were metabolically labelled with palmitate analogue 
17ODYA and lysed. 17ODYA labelled proteins were tagged in a click chemistry reaction with biotin-azide, purified on streptavidin-coupled 
beads and analysed for the presence of WBP1L with anti-FLAG antibody (upper panel) or FLOTILLIN-2 as a representative of endogenous 
palmitoylated proteins (middle upper panel). WBP1L expression in cell lysates (middle lower panel) and comparable loading were verified by 
immunoblotting with antibodies to FLAG-tag (WBP1L) or FLOTILLIN-2, respectively (N = 3)
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2.6 | Statistics
Results represent means ± SEM. If not specified otherwise, P-values 
were calculated using two-tailed Student's t test, one-way ANOVA 
or Q test. N represents number of animals or values per group or 
number of independent experiments.
3  | RESULTS
3.1 | WBP1L is a palmitoylated glycoprotein broadly 
expressed in haematopoietic cells
Analysis of WBP1L protein and mRNA expression in murine 
and human haematopoietic system with a newly generated 
polyclonal rabbit antibody (Figure 1A) and with Genevestigator 
tool, respectively, revealed that WBP1L is broadly expressed 
across multiple human and murine haematopoietic cell subsets 
(Figure 1B and S1). In addition and in agreement with previous 
reports of deregulated WBP1L expression in ETV6-RUNX1+ BCP-
ALL, we have found elevated levels of WBP1L protein in REH cell 
line, which is derived from ETV6-RUNX1+ BCP-ALL. (Figure 1C 
and S2A). Interestingly, the genetic deletion of ETV6-RUNX1 in 
REH cells (Figure S2B,C) did not alter WBP1L expression in these 
cells (Figure 1D).
Imaging of murine bone marrow-derived macrophages trans-
duced with retroviral vector coding for murine WBP1L fused to EGFP 
revealed relatively broad distribution of WBP1L-EGFP within these 
cells. We have observed co-localization with plasma membrane, 
Golgi, endoplasmic reticulum, and to a limited extent with lysosomes 
and/or other acidic organelles (Figure S3). On the other hand, no 
co-localization with mitochondria could be detected (Figure S3).
The N-terminal part of WBP1L protein is highly conserved 
among major vertebrate classes (Figure S4). This region contains 
several conserved motifs, including potential N-glycosylation 
(NXS) and palmitoylation sites (Figure 1E and S4). Indeed, we 
could confirm that WBP1L is both glycosylated and palmitoylated 
(Figure 1F,G).
3.2 | WBP1L interacts with NEDD4-family E3 
ubiquitin ligases
Cytoplasmic part of WBP1L contains three WW domain binding mo-
tifs ([L/P]PXY) (Figure 1E and S4). It has been speculated that they 
may interact with WW domains of NEDD4-family ubiquitin ligases.11 
F I G U R E  2   WBP1L binds multiple NEDD4-family E3 ubiquitin ligases. (A) Data from two independent mass spectrometry analyses (I. 
and II.) of WBP1L binding partners. Wbp1l−/− monocyte/macrophage progenitors were transduced with the constructs coding for WBP1L-
FLAG-STREP or EGFP with the same tag. The cells were stimulated for 2 min with CXCL12 or left untreated. Tagged proteins with their 
binding partners were isolated by tandem purification and subjected to mass spectrometry analysis. The data are presented as colour-
coded intensities obtained by label-free quantification of NEDD4-family E3 ubiquitin ligases. Values represent number of peptides used for 
intensity calculation/ number of unique peptides. Samples, where no peptides from a particular E3 ligase were detected, are coloured in grey 
(B) Label-free quantification of interacting E3 ligases from mass spectrometry experiment. Combined average intensities from both CXCR4 
stimulated and non-stimulated samples are plotted (experiment I. form (A) only). (C) mRNA expression of NEDD4-family E3 ubiquitin ligases 
in immortalized monocyte/macrophage progenitors (iProgenitors). Plotted in brown are those ligases that interacted with WBP1L in mass 
spectrometry experiments (N = 3). (D) WBP1L interaction with NEDD4-family E3 ligases is dependent on WW binding motifs in WBP1L 
N-terminus. HEK293 cells were transfected with WBP1L-Myc or WBP1LΔN-Myc (with segment containing all WW binding motifs deleted) 
together with ITCH or WWP2. Following WBP1L immunoprecipitation, the isolated material and the original lysates were immunoblotted 
with antibody to ITCH or WWP2 and various controls as indicated (N = 3). (E) mRNA expression of NEDD4-family E3 ligases in BMDM. 
Plotted in brown are those ligases that interacted with WBP1L in mass spectrometry experiment (N = 3). (F) Endogenous interaction of 
WBP1L with WWP1 in BMDM. WBP1L immunoprecipitates from WT or Wbp1l−/− BMDM were immunoblotted with antibody to WWP1 and 
WBP1L. Input lysates were probed with antibody to WWP1 (N = 3). See also Figure S5
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However, this family has nine different members. To investigate 
whether WBP1L interacts with any of these ligases, we have expressed 
a FLAG-STREP-tagged WBP1L construct in immortalized monocyte/
macrophage progenitors. We have selected this cell type because of 
a relatively high level of Wbpl1 mRNA in myeloid progenitors (Figure 
S1). We isolated the FALG-STREP-tagged construct together with its 
associated binding partners from the lysates of these cells via a tan-
dem purification on anti-FLAG and Streptactin beads. Mass spec-
trometry analysis of the isolated material revealed that WBP1L indeed 
interacts with several members of NEDD4-family. In this particular 
cell type, WWP2 was the most prominent. However, ITCH, WWP1 
and NEDD4L could also be detected in one experiment (Figure 2A). 
Interestingly, the mass spectrometry signal intensities corresponded to 
the relative expression levels of these NEDD4-family members in im-
mortalized monocyte/macrophage progenitors (Figure 2B,C). On the 
other hand, not all NEDD4-family members expressed in these cells 
could be co-isolated with WBP1L. These data suggest a certain level of 
WBP1L selectivity for individual NEDD4-family members.
To find out whether NEDD4-family ligases bind WBP1L via its 
[L/P]PXY WW domain binding motifs we have co-expressed the 
two highest scoring NEDD4-family ligases from the mass spec-
trometry experiment, WWP2 or ITCH, with wild-type WBP1L 
construct or with mutant WBP1LΔN lacking the membrane-prox-
imal WW domain binding sequences (Figure 2D) in HEK293 cells. 
These cells allow for relatively high level of overexpression, which 
was ideal for reliable identification of NEDD4 family binding sites 
in WBP1L. Both E3 ligases could be readily co-immunoprecipi-
tated with wild-type WBP1L but not with WBP1LΔN (Figure 2D). 
These data were further confirmed in a similar experiment in J774 
macrophage-like cell line, which expresses relatively high level of 
F I G U R E  3   WBP1L regulates ubiquitination and expression of NEDD4-family E3 ubiquitin ligases and CXCR4. (A) HEK293 cells 
were cotransfected with individual Myc-tagged NEDD4-family E3 ubiquitin ligases and non-tagged WBP1L or its mutant lacking PPPY 
WW domain interacting motif. E3 ligases were immunoprecipitated via the Myc-tag from the lysates of these cells and subjected to 
immunoblotting with anti-MYC-tag or anti-UBIQUITIN antibody. (B) ITCH and WWP2 stability in HEK293 cells in the presence of 
WBP1L-MYC, WBP1L ΔC-MYC (deletion of almost entire intracellular part of WBP1L except for WW binding motifs) or WBP1L ΔN-MYC 
(deletion of WW binding motifs). Lysates from HEK293 cells transfected with ITCH-MYC or WWP2-MYC and WBP1L constructs were 
immunoblotted with antibody to MYC-tag to visualize ITCH, WWP2 and all forms of WBP1L and with antibody to ACTIN. Quantifications of 
the data are plotted as values normalized to ACTIN signal and then further normalized to experiment average to allow for comparison among 
the experiments (N = 3). (C) WBP1L-mediated increase in CXCR4 ubiqutination and down-regulation of CXCR4 protein levels in HEK293 
cells. WBP1L-MYC, WBP1LΔC-MYC or WBP1LΔN-MYC were cotransfected with CXCR4-HA followed by CXCR4 imunoprecipitation and 
immunoblotting with antibodies to ubiquitin or HA-tag. Lysates were probed with antibodies to HA-tag (CXCR4), MYC-tag (WBP1L) or 
GAPDH (N = 3). For quantification, ubiquitination was normalized to HA-tag (CXCR4) signal (left panel) and CXCR4 expression to GAPDH 
(right panel). Both were further normalized to experiment average to allow for comparison among the individual experiments
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ITCH (not shown). The endogenous ITCH could be co-isolated with 
wild-type WBP1L but not with WBP1LΔN from these cells (Figure 
S5). To confirm the interaction of WBP1L with a NEDD4-family 
member at the endogenous protein level, we have selected bone 
marrow-derived macrophages (BMDM) which express the high-
est levels of WBP1L among the cell types we have tested so far 
(Figure 1B). WWP1, which is the most abundant NEDD4-family 
member in this cell type (Figure 2E), could be co-isolated with 
WBP1L in this experiment (Figure 2F).
3.3 | WBP1L regulates ubiquitination and 
expression level of NEDD4-family E3 ubiquitin 
ligases and of CXCR4
Interaction with WW domain binding motifs is known to result in 
the activation and autoubiquitination of NEDD4-family ubiqui-
tin ligases.14,15 To test whether WBP1L can activate NEDD4 fam-
ily members, we have cotransfected WBP1L-interacting (Figure 2A) 
NEDD4-family ligases with wild-type WBP1L, or its mutant lacking 
one of the conserved WW domain binding motifs, into HEK293 cells. 
This analysis demonstrated that cotransfection with wild-type but 
not mutant WBP1L resulted in a substantial increase in ubiquitina-
tion of all these ligases, which is a sign of their activation (Figure 3A). 
Published work suggests that in the case of ITCH this ubiquitination 
results in down-regulation of its protein levels, while WWP2 appears 
relatively resistant to this negative feedback regulation. Thus, to fur-
ther explore the mechanism of how WBP1L regulates these ubiquitin 
ligases, we co-expressed wild-type WBP1L, WBP1LΔN or WBP1LΔC 
(lacking C-terminal region of unknown function) with ITCH or WWP2 
in HEK293 cells. Co-expression of ITCH with wild-type WBP1L and 
WBP1LΔC resulted in significantly reduced ITCH protein level when 
compared to co-expression with WBP1LΔN. As expected, this effect 
was much more limited in case of WWP2 (Figure 3B).
One of the best-studied targets of NEDD4-family ubiquitin li-
gases in the haematopoietic system is the chemokine receptor 
CXCR4. It is involved in the maintenance of haematopoietic stem 
and progenitor cells and in promoting niche interactions in the bone 
marrow. It is also thought to support the survival and treatment re-
sistance of leukaemic cells.16,17 Based on these features, we have se-
lected CXCR4 for a similar set of experiments to test whether WBP1L 
regulates its protein expression levels and ubiquitination. Indeed, 
co-expression of WBP1L with CXCR4 in HEK293 cells resulted in 
increased ubiquitination of CXCR4 (presumably by an endogenous 
NEDD4-family ligase). This effect was almost completely abolished 
by mutation of the WW domain binding motifs (WBP1LΔN) while 
deletion of the C-terminal sequence (WBP1LΔC) had a more limited 
effect (Figure 3C). CXCR4 ubiquitination was further accompanied 
by reduction in CXCR4 protein levels (Figure 3C). We also observed 
that WBP1L co-expression resulted in a striking increase in CXCR4 
electrophoretic mobility (Figure 3C). The reason for this mobility 
shift is at present unknown.
F I G U R E  4   ShRNA-mediated down-regulation of WBP1L results in enhanced CXCR4 signalling in human and murine cell lines. (A, B) 
WBP1L immunoprecipitates from REH cells (A) or immortalized monocyte/macrophage progenitors (B) transduced with Wbp1l shRNA 
were stained with WBP1L antisera to demonstrate WBP1L down-regulation. Equal input of lysates to immunoprecipitation was verified by 
ACTIN immunoblotting. Quantification of multiple experiments (after normalization to ACTIN signal) was plotted as a percentage of WBP1L 
expression in non-transduced cells. (C, D) ERK1/2 and AKT phosphorylation downstream of CXCR4 in REH cells (C) and immortalized 
monocyte/macrophage progenitors (iProgenitors) (D), where WBP1L was down-regulated by shRNA. Cells were stimulated with 100 nmol/L 
CXCL12, lysed and subjected to Western blot analysis of ERK1/2 and AKT phosphorylation. Data represent mean of fluorescence intensity 
normalized to GAPDH. The P-value was calculated to compare maximum responses of cells transduced with non-silencing control and 
silencing shRNA. Asterisks denote significant differences in individual time-points. (N = 4)
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3.4 | WBP1L inhibits CXCR4 signalling in 
murine and human cell lines
To analyse the effects of the endogenous WBP1L on CXCR4, we 
have selected two cell lines where the expression of WBP1L and/
or CXCR4 is highly relevant. These included human leukaemic cell 
line REH as a representative of ETV6-RUNX1+ leukaemia, where 
we have down-regulated WBP1L by a single shRNA specific for 
human WBP1L and immortalized murine monocyte/macrophage 
progenitors as a representative of bone marrow progenitors, where 
F I G U R E  5   Altered leucocyte homeostasis in WBP1L-deficient mice. (A) Western blot analysis of WBP1L immunoprecipitates or whole 
cell lysates prepared from WT and Wbp1l−/− cells. mOPAL-01/03 antibodies were used for immunoprecipitation and WBP1L rabbit antisera 
for Western blotting. N = 3 (bone marrow), N = 5 (BMDM). (B) Flow cytometry analyses of E10.5 WT and Wbp1l−/− yolk sac cell subsets. 
Primitive macrophages were defined as Ter119− CD11b+ F4/80+. (C) Absolute numbers of splenocytes obtained from WT and Wbp1l−/− 
mice and flow cytometry analyses of WT and Wbp1l−/− splenocytes defined using the following markers: B cells (B220+), MZ B cells (B220+, 
AA4.1−, CD23−/low, CD1d+), T cells (CD3+), macrophages (F4/80+, CD11b int), DC (CD11c+, LY6C−/low) and neutrophils (LY6G+, CD11b+, LY6C−). 
(D) Flow cytometry analyses of WT and Wbp1l−/− leucocytes in the peritoneum, defined using the following markers: B1 cells (SSClow, FSClow, 
B220+, CD23−/low), B2 cells (SSClow, FSClow, B220+, CD23+) and macrophages (large peritoneal macrophages, CD11bhigh,F4/80high). (E) Flow 
cytometry analyses of WT and Wbp1l−/− bone marrow cell subsets, defined using the following markers: T cells (CD3+), monocytes (LY6C+, 
CD11b+, LY6G−, CD19−, TER119−, CD3−, NK1.1−), neutrophils (KIT−, B220−, TER119−, CD3−, LY6Ghigh) (F) Flow cytometry analyses of stem 
and progenitor cells in the bone marrow. Cell subsets were defined using following markers: common myeloid progenitors—CMP (lin−, c-kit+, 
CD34+, CD16/32neg−low, SCA1−), granulocyte-monocyte progenitors—GMP (lin−, KIT+, CD34+, CD16/32High, SCA1−), megakaryocyte-erythroid 
progenitors—MEP (lin−, KIT+, CD34−, CD16/32−, SCA1−) and LSK (lin−, KIT+, SCA1+). (G) Flow cytometry analysis of bone marrow B cell 
subsets. B cells (B220+), pro-B cells (CD43+, B220+, IgM−), pre-B cells (CD43−, B220low, IgM−), immature B cells (CD43−, B220low, IgM+) and 
mature B cells (CD43−, B220high, IgM+)
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we used a different shRNA targeting murine Wbp1l (Figure 4A,B). 
After stimulation with CXCR4 ligand CXCL12, these cells showed 
enhanced activity of downstream signalling pathways, resulting in 
increased phosphorylation of ERK1/2 and AKT (Figure 4C,D and S6). 
CXCR7, another known receptor for CXCL12, did not contribute to 
the signalling output under these conditions (Figure S7). These data 
demonstrated that WBP1L is involved in the negative regulation of 
CXCR4 signalling.
3.5 | Altered haematopoiesis in Wbp1l-
deficient mice
To further analyse the physiological function of WBP1L, we have 
acquired Wbp1l-deficient mouse strain Wbp1ltm2a(EUCOMM)Hmgu 
(hereafter referred to as Wbp1l−/−) from the International Mouse 
Phenotyping Consortium. These mice appeared grossly normal and 
healthy, were born in normal Mendelian ratios and did not express 
WBP1L protein (Figure 5A).
To characterize the haematopoietic system in Wbp1l−/− mice, 
we have analysed major cell subset frequencies in adult mice and in 
embryos. The embryonic haematopoietic cell numbers were grossly 
normal with small increases in the yolk sac CD45+ KIT− cells and 
CD11b+ F4/80+ yolk sac macrophages (Figure 5B). In the peripheral 
tissues of the adult mice, there was a significant increase in mar-
ginal zone B cell fraction in the spleen (Figure 5C) and a reduction 
in B1 cell percentages in the peritoneal cavity (Figure 5D). We also 
observed increased frequencies of splenic dendritic cells in Wbp1l−/− 
mice (Figure 5C). Otherwise, the frequencies of other leucocyte 
subsets found in peripheral tissues were normal (Figure 5C,D). Bone 
marrows from Wbp1l−/− animals showed the same cell counts as wild-
type bone marrows (Figure 5E). Most of bone marrow cell subsets 
were also found in normal numbers, including T cells, monocytes, 
neutrophils (Figure 5E) and the majority of progenitor populations 
(Figure 5F). However, there were two notable exceptions. First, the 
overall B cell percentages in the bone marrow were significantly 
reduced (Figure 5G). The reduction was most pronounced in early 
developmental stages (pro- and pre-B cells). At the later stages, in-
cluding immature and mature B cells a similar trend was observed, 
but it was outside the threshold for statistical significance (P-values 
.06 and .08, respectively) (Figure 5G). The cell cycle of B cell pro-
genitors was not substantially changed with the exception of a very 
F I G U R E  6   Enhanced engraftment of Wbp1l−/− bone marrow. (A) Ly5.2+ bone marrow (WT or Wbp1l−/−) was mixed with Ly5.1+ bone 
marrow (always WT) in a ratio 1:1 and 2 × 106 cells were transplanted into Ly5.1 lethally irradiated mice. Mice were analysed 2 months post-
transplantation. Flow cytometry analyses show the ratio between Ly5.2 and Ly5.1 cells in the bone marrow, blood and spleen. (B) LSK cells 
sorted from Ly5.2+ bone marrow (WT or Wbp1l−/−) were mixed with LSK from Ly5.1/Ly5.2+ heterozygous bone marrow (always WT) in a ratio 
1:1 and 20 000 cells together with support of 0.5 × 106 Ly5.1 bone marrow cells were injected into tail vain of Ly5.1 lethally irradiated mice. 
Data represent the ratio between Ly5.2+ and Ly5.1/Ly5.2+ cells detected in the recipient blood 4 wk post injection. One of two independent 
experiments is shown (N ≥ 8). (C) Ly5.2+ bone marrow (WT or Wbp1l−/−) was mixed with Ly5.1/Ly5.2+ heterozygous bone marrow (always 
WT) in a ratio 1:1 and 2 × 106 cells were transplanted into Ly5.1 lethally irradiated mice. At indicated time-points, the ratio between Ly5.2 
and Ly5.1/Ly5.2 cells in blood was measured by flow cytometry. (D) Homing of WT and Wbp1l−/− bone marrow cells in a competitive set-up. 
WT or Wbp1l−/− bone marrow (Ly5.2+) was each combined with WT bone marrow from Ly5.1/Ly5.2+ heterozygotes in a ratio 1:1 and 2 × 106 
cells were injected into the tail vain of sublethally irradiated recipient (Ly5.1+). Data represent the ratio between Ly5.2+ and Ly5.1/Ly5.2+ cells 
detected in the recipient bone marrow 16 h post injection (N ≥ 8). (E) Competitive bone marrow transplantation was performed as in (C) and 
3 wk after the transplantation expression of Ki67 proliferation marker was measured in transplanted cells
1988  |     BORNA et Al.
small but significant increase in G1 phase pre-B cells in Wbp1l−/− mice 
(Figure S8). Second, Lin−SCA1+KIT+ (LSK) cells encompassing early 
progenitors and stem cells (HSPC) showed slightly but significantly 
increased percentages in these animals (Figure 5F).
To test their functionality in vivo, we performed a competitive 
bone marrow transplantation assay, whereby we mixed wild-type 
or Wbp1l−/− Ly5.2 cells with wild-type Ly5.1 bone marrow cells in 
a 1:1 ratio and transplanted these mixtures into lethally irradiated 
recipient mice (Ly5.1). Nine weeks later, we have analysed their en-
graftment. Strikingly, Wbp1l−/− bone marrow engrafted significantly 
better and the ratio between Wbp1l−/− and wild-type cells increased 
from 1:1 to ca 3:1 (Figure 6A), whereas wild-type Ly5.2 and Ly5.1 BM 
engrafted with equal efficiency. The difference could be observed 
across all bone marrow leucocyte subsets analysed except for LSK 
cells, where a similar trend in favour of Wbp1l−/− cells was also present 
but was not statistically significant (Figure S9). The difference was 
also maintained in the periphery, where the ratio between Wbp1l−/− 
and wild-type cells was roughly 2:1 (Figure 6A). Similar difference 
in engraftment efficiency was also observed when we transplanted 
sorted LSK cells in the 1:1 ratio (Figure 6B). Next, we investigated 
how this ratio changes with time. A significant difference between 
the engraftment efficiency could be observed as early as 3 weeks 
after the transplantation and was maintained till at least 18 weeks 
after the transplantation (Figure 6C). The increased efficiency in the 
bone marrow engraftment was not the result of increased homing 
to the bone marrow or increased proliferation, which did not dis-
play any alteration (Figure 6D,E). Collectively, these data are show-
ing negative role of WBP1L in HSPC function. Persistence of the 
engraftment advantage for more than 16 weeks suggests that the 
haematopoietic system is affected already at the level of haemato-
poietic stem cells.
3.6 | Compensatory mechanisms restore CXCR4 
signalling when WBP1L is lost in the germline, but the 
effects of WBP1L deficiency on CXCR4 signalling can 
be observed upon its acute deletion
Part of the data described above are consistent with CXCR4 hyper-
activity. However, the same homing capacity of the wild-type and 
Wbp1l−/− bone marrow cells (Figure 6D) is incompatible with enhanced 
CXCR4 function. These results prompted us to test whether bone mar-
row cells from Wbp1l−/− mice display similar CXCR4 dysregulation as 
shRNA-treated cell lines. Surprisingly, we did not observe any altera-
tions in CXCL12-triggered ERK phosphorylation in bone marrow cells 
from Wbp1l−/− mice (Figure 7A). This result was in disagreement with 
our analysis of the effects of shRNA-mediated WBP1L down-regula-
tion in cell lines (Figure 4). To exclude the possibility that enhanced 
CXCR4 signalling observed there was the result of non-specific off-tar-
get effects of Wbp1l shRNAs, we expressed shRNA targeting Wbp1l in 
immortalized monocyte/macrophage progenitors from wild-type and 
Wbp1l−/− mice. Because of the absence of WBP1L, only non-specific 
activity of Wbp1l shRNA can be detected in Wbp1l−/− progenitors. As 
expected, Wbp1l shRNA significantly enhanced CXCL12-triggered 
ERK activation in wild-type cells. On the other hand, only negligible 
insignificant changes were detected in Wbp1l−/− cells (Figure 7B). These 
results demonstrated that the effects of Wbp1l shRNA are dependent 
on Wbp1l and, thus, specific. When we used the same cells in an in 
vivo homing experiment, we observed that WBP1L down-regulation 
significantly enhanced bone marrow homing of wild-type cells, when 
compared to Wbp1l−/− cells (Figure 7C). This outcome is consistent with 
the results of our in vitro analyses showing that WBP1L negatively 
regulates activity of CXCR4.
To definitely prove the validity of our shRNA data, we have 
generated a mouse strain Wbp1lfl/fl-CreERT where the Wbp1l gene 
can be acutely inactivated upon injection of 4OH-tamoxifen. Acute 
Wbp1l deletion in this model resulted in enhanced ERK phosphor-
ylation in response to CXCL12 stimulation in total bone marrow as 
well as in several major subsets, including T cells, monocytes and 
neutrophils, whereas in B cells, the difference was small and not 
statistically significant (Figure 7D and S10). No effects of WBP1L 
deficiency on total ERK expression were observed (Figure 7E). The 
enhanced CXCR4 signalling did not translate to any immediate effect 
on steady-state numbers of major bone marrow and splenic cell sub-
sets (Figure S11A). However, it is likely that only much more substan-
tial increase in CXCR4 signalling would be needed to alter leucocyte 
bone marrow retention within this timescale.
The data presented above suggested that the effects of WBP1L 
down-regulation can only be observed after its acute deletion. To 
further address this possibility, we have established primary culture 
of isolated KIT+ bone marrow cells from Wbp1lfl/fl-CreERT mice, where 
Wbp1l could be deleted by 4OH-tamoxifen. Importantly, cells cultured 
outside the bone marrow are not exposed to continuous CXCL12 
stimulation and desensitization and are, thus, having high expression 
of CXCR4 and stronger signalling capacity. In agreement with our pre-
vious observations, after acute Wbp1l deletion by CRE recombinase 
(but not after germline deletion), these progenitors showed increased 
ERK phosphorylation in response to CXCL12 stimulation (Figure 7F 
and S11B). Wbp1l deletion also resulted in an increase in steady-state 
CXCR4 surface expression with no other effects on the rate of 
CXCL12-triggered receptor internalization in these cells (Figure 7G and 
S11C). The same increase in CXCR4 expression was also observed on 
KIT+ progenitors from peripheral blood of animals after acute Wbp1l 
deletion (Figure 7H). Similar, though not significant, trend was also 
observed when CXCR4 was measured on fixed and permeabilized 
cells (Figure S11D). Finally, cells with acute Wbp1l deletion showed in-
creased migration towards CXCR4 ligand CXCL12 in a transwell assay 
in vitro (Figure 7I) and increased bone marrow homing efficiency in 
vivo (Figure 7J). These data confirm that WBP1L negatively regulates 
CXCR4 expression and signalling in primary cells.
4  | DISCUSSION
Expression of the WBP1L gene is heightened in ETV6-RUNX1+ 
paediatric BCP-ALL and was shown to correlate with favourable 
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treatment response.1-3 However, the function of its protein prod-
uct WBP1L in healthy and leukaemic cells has not been investigated. 
Here, we attempted to uncover its physiological function. Our initial 
analysis shows that WBP1L binds several NEDD4-family E3 ubiqui-
tin ligases and its deficiency results in augmented surface expres-
sion and signalling of CXCR4, one of their known target proteins. 
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At the organismal level, WBP1L deficiency resulted in perturbations 
in B cell development and increased ability of bone marrow stem 
and progenitor cells to reconstitute haematopoietic system after 
the bone marrow transplantation. In addition, acute Wbp1l deletion 
resulted in increased progenitor homing to the bone marrow. How 
much of this phenotype can be attributed to CXCR4 hyperactivity 
is still an open question. There are at least two other mouse models 
that show increased CXCR4 activity. One of these strains carries a 
mutation in CXCR4 that prevents its desensitization and down-reg-
ulation (CXCR4WHIM). The same mutation in humans causes immuno-
deficiency known as WHIM syndrome.18-20 CXCR4WHIM mice display 
a similar selective dysregulation in the bone marrow B cell compart-
ment as Wbp1l−/− mice with the reduction in B cell percentages that 
is most profound at the B cell progenitor level.20 They also show 
increase in marginal zone B cell percentages. On the other hand, 
some of their symptoms were not detected in Wbp1l−/− mice, includ-
ing blood neutropenia and lymphopenia and reduced spleen size.20 
Increased CXCR4 expression and CXCR4-mediated signalling were 
also observed in mice deficient in the expression of BAR domain 
containing adaptor protein Missing In Metastasis (MIM). In these 
animals, leucocyte development and percentages appeared largely 
normal and no leukopenia has been observed. Rather they showed 
slightly increased white blood cell counts and splenomegaly.21,22 
Even though MIM deficiency has a number of CXCR4-independent 
effects, these data show that enhanced CXCR4 activity does not 
have to lead to leukopenia in the peripheral tissues, nor to major 
alterations in leucocyte subset numbers and frequencies in the bone 
marrow. It is possible that the lack of receptor desensitization rather 
than alterations in peak signal intensity may be the key factor driving 
peripheral leukopenia in CXCR4WHIM mice.
Since in mice with germline Wbp1l deletion we have not observed 
up-regulation in CXCR4 activity, it is difficult to unequivocally an-
swer the question if alterations in Wbp1l−/− B cell development are 
caused by CXCR4 dysregulation. This phenotype is strikingly similar 
to the one observed in CXCR4WHIM animals. It is possible that not all 
haematopoietic cell subsets are able to compensate for the loss of 
WBP1L. Early B cell progenitors represent a relatively small popula-
tion, and their WBP1L expression based on the data from ImmGen 
consortium23 is similar to other B cell subsets (not shown). The op-
tions to analyse their CXCR4 signalling pathways are relatively lim-
ited. Those that can be analysed by flow cytometry, including ERK 
and STAT3 phosphorylation, as well as calcium response appear to 
be hypo/non-responsive in this particular cell type despite clearly 
measurable CXCR4 expression (not shown). As a result, B cell pro-
genitors contribute very little to ERK phosphorylation of the entire 
B cell pool measured in our experiments where the more mature 
stages dominated the response. The other pathways we were not 
able to analyse in this relatively rare subpopulation and so it is still 
F I G U R E  7   Acute loss of WBP1L results in enhanced CXCR4 signalling but germline deficiency is compensated for. (A) ERK1/2 
phosphorylation downstream of CXCR4 in WT and Wbp1l−/− (germline deletion) bone marrow cells. Cells were stimulated with 100 nmol/L 
CXCL12, fixed, stained for phosphorylated ERK1/2 and analysed by flow cytometry. Data represent percentage of responding cells (N = 6). 
P-value was calculated for maximum response of WT and Wbp1l−/− cells regardless of the time-point where it was reached. (B) Erk1/2 
activation after CXCL12 stimulation (100 nmol/L) of immortalized monocyte/macrophage progenitors (iProgenitors) from WT and Wbp1l−/− 
mice and of the same cells transduced with Wbp1l shRNA. Erk phosphorylation was measured by flow cytometry of fixed and permeabilized 
cells stained with fluorescent P-Erk1/2 antibody. Peak response detected during 5 min measurement is shown. Data are represented as 
medians of fluorescence intensity (N = 3). P-values were calculated using 1way ANOVA with Bonferroni's multiple comparison test. (C) WT 
cells transduced or not with Wbp1l shRNA were mixed 1:1 and their bone marrow homing ability was analysed as in Figure 6D. As a control 
Wbp1l−/− cells transduced or not with Wbp1l shRNA and also mixed in a ratio 1:1 were used. Ratios of shRNA transduced and non-transduced 
cells are plotted for each genotype (n = 8). P-value was calculated for the differences between these two ratios. Significant outliers were 
discarded based on q test. As not all cells expressed shRNA containing vector after transduction, the true ratio was lower than 1:1 at the 
time of injection. The final data were normalized to this true ratio. (D) CXCR4 signalling in bone marrow cell subsets after acute deletion 
of Wbp1l. In the top row, CreERT expressing cells treated either with tamoxifen or vehicle (corn oil) are compared. In the bottom row, the 
comparison is made between tamoxifen-treated Wbp1lfl/fl-CreERT and Wbp1lfl/fl (without CreERT) bone marrow cells. Cells were stimulated 
with 100 nmol/L CXCL12, fixed, stained for extracellular markers and intracellular P-ERK and analysed by flow cytometry. Data represent 
percentage of responding cells from whole bone marrow (N = 7), T cells (CD3+, N = 7/8), monocytes (Ly6C+ Ly6G−, N = 11) and neutrophils 
(Ly6G+ Ly6C−,N = 7). Significant outliers were discarded based on q test. P-value was calculated for maximum response (regardless of the 
time-point at which this maximum was reached). In addition, significant differences in individual time-points are labelled with asterisks. 
(E) Expression of total ERK1/2 in the bone marrow cells where Wbp1l was deleted as in (D). Protein level was measured using Western 
blot. ERK1 and ERK2 were probed separately and signal was summed and normalized to actin loading control (N ≥ 5) (F). CXCR4 signalling 
in in vitro 4-hydroxytamoxifen treated KIT+ progenitors isolated from Wbp1lfl/fl-CreERT and Wbp1lfl/fl (without CreERT) bone marrow. ERK 
phosphorylation was measured after stimulation with 100 nmol/L CXCL12 by flow cytometry on fixed and permeabilized cells. Peak 
response detected during 5 min measurement is shown. One of two independent experiments is shown, N = 6. (G) CXCL12-induced changes 
of CXCR4 surface expression on KIT+ bone marrow progenitors. These cells were isolated from Wbp1lfl/fl-CreERT and Wbp1lfl/fl bone marrow, 
treated with 4-hydroxytamoxifen to induce Wbp1l deletion and stimulated with CXCL12 for indicated time intervals. FACS data are plotted 
as median fluorescence intensities (left graph) or as percentage of expression level on non-stimulated cells (right graph) (n = 7). (H) CXCR4 
expression on KIT+ progenitors detected in the blood of tamoxifen-treated Wbp1lfl/fl-CreERT and Wbp1lfl/fl mice. Significant outlier was 
discarded based on q test (N = 10). (I) Migration of 4-hydroxytamoxifen-treated KIT+ progenitors from Wbp1lfl/fl-CreERT and Wbp1lfl/fl mice 
towards 500 nmol/L CXCR4 in a transwell assay in vitro (N = 5). (J) Ly5.2+ KIT+ progenitors (from Wbp1lfl/fl-CreERT or Wbp1lfl/fl mice, treated 
with 4-hydroxytamoxifen) were mixed 1:1 with Ly5.1/Ly5.2+ heterozygous KIT+ progenitors from WT mice and 107 cells were injected into 
Ly5.1 sublethally irradiated recipients. After 16 h, the ratio between Ly5.2 and Ly5.1/Ly5.2 cells in the bone marrow was measured by flow 
cytometry (N ≥ 11)
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possible that reduction in B cell progenitor numbers in Wbp1l−/− mice 
is caused by some aspect of CXCR4 signalling, which we could not 
measure.
WBP1L may also have other functions besides regulation of 
CXCR4. They may be responsible for a part of the phenotype of 
WBP1L-deficient cells and animals. WBP1L binds multiple NEDD4 
family members and very likely other proteins, which can result in 
pleiotropic effects on leucocyte biology. It has been shown that in 
competitive transplantation assay HSPC with only one functional 
CXCR4 allele perform better than wild-type cells, which perform 
better than CXCR4WHIM cells, clearly showing an inverse correlation 
between CXCR4 activity and transplantation efficiency.24,25 This 
observation is rather counterintuitive and opposite to the results 
we obtained with Wbp1l−/− cells. An explanation suggested in these 
studies was that CXCR4 promotes haematopoietic stem cell quies-
cence leading to competitive disadvantage when CXCR4 signalling 
is up-regulated. This leads to the conclusion that though CXCR4 
role cannot be completely excluded by our experiments, effects of 
WBP1L on transplantation efficiency are likely CXCR4-independent. 
The molecular mechanism of how WBP1L regulates bone marrow 
engraftment will have to be addressed in future studies. On the 
other hand, functional effects of acute down-regulation of WBP1L 
are more clearly connected to CXCR4, leading to increased surface 
expression of CXCR4, increased CXCR4 signalling and improved 
homing efficiency, similar to mouse models with increased CXCR4 
activity.
It is at present unclear what is the reason for the unequal effects 
of the acute and constitutive OPAL1 deletion on CXCR4 signalling. 
We can speculate that WBP1L may be rather general regulator of 
expression and/or activity of NEDD4 family ligases. However, there 
are many additional mechanisms regulating these enzymes. In the 
majority of cases, these might be able to compensate for the loss 
of WBP1L in the long-term. However, their ability to rapidly react 
to acute WBP1L loss would likely be more limited, as it may require 
changes in the gene expression pattern or other time-consuming 
adaptations.
Another important question is the role that WBP1L potentially 
plays in leukaemia. The WBP1L gene is a target gene of ETV6, which 
suppresses its expression.4 In ETV6-RUNX1+ BCP-ALL, one allele of 
ETV6 is inactivated by fusion with RUNX1, while the other is often 
inactivated as well.26 This could explain the increase of WBP1L ex-
pression in ETV6-RUNX1+ BCP-ALL. It is also in agreement with our 
data showing that in REH cells (which already have both ETV6 alleles 
inactivated) ETV6-RUNX1 genetic deletion did not have any further 
effect on WBP1L expression. ETV6 inactivation likely represents 
part of the mechanism leading to the development of leukaemia 
and defining its features. In principle, WBP1L in this context can 
have two different functions. First, negative regulation of CXCR4 
by WBP1L could dampen the interactions of leukaemic (stem) cells 
with protective bone marrow niches, making them more sensi-
tive to treatment. Second, WBP1L may also have negative effect 
on leukaemic stem cells similar to its negative regulatory effects 
on HSPCs that were revealed in our competitive transplantation 
experiment. Our data do not specifically address the role of WBP1L 
in leukaemia. However, the effects of WBP1L deficiency on normal 
haematopoiesis that we observed here and the fact that WBP1L is 
an ETV6 target gene make WBP1L a relevant target of future re-
search in this field.
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